Sahajanand Medical Technologies Limited IPO

The company is subject to extensive regulatory requirements in applicable jurisdictions. Any adverse action by any authority against the company would negatively impact its ability to offer the company's products to the company's clients and adversely impact its business and prospects.

The company's manufacturing facilities are subject to certain risks, including quality control issues, disruptions in infrastructure facilities, and obsolete plant and machinery, which could increase its manufacturing costs or interrupt the company's operations and adversely impact its reputation, sales and strategies.

The company is required to obtain, renew or maintain statutory and regulatory permits, licenses and approvals in relation to the company's manufacturing facilities, and any delay or inability in obtaining, renewing or maintaining such permits, licenses and approvals could result in an adverse effect on its business, financial condition, cash flows and results of operations. Further, the company's manufacturing facilities are subject to periodic inspections and audits by various regulatory authorities and clients.

The company is dependents on the continued supply of raw materials and components, the supply and cost of which can be subject to significant variation due to factors outside our control. Additionally, the company is dependent on the company's suppliers (our top 10 suppliers contributed to 64.37%, 58.88% and 62.87% of total purchases in Fiscal 2025, Fiscal 2024 and Fiscal 2023, respectively) for certain raw materials and components and a single supplier for certain components and an inability to procure the required quality and quantity, at competitive prices, the company's business, financial condition, cash flows and results of operations may be adversely affected.

A majority of the company's revenues are from the sale of Vascular Intervention devices (contributed to 65.86%, 68.57% and 71.99% of its revenue from operations in Fiscals 2025, 2024 and 2023, respectively). Additionally, the sale of the Supraflex Cruz contributed to 42.06%, 47.84% and 44.91% of the company's revenue from operations in Fiscals 2025, 2024 and 2023, respectively. Any adverse impact on sales of products within this vertical, or of the Supraflex Cruz would adversely affect its business, results of operations and profitability.

The company may not be able to implement its business strategies or sustain and manage the company's growth.

Regulatory uncertainty associated with pricing of medical devices could adversely affect the marketing, pricing and demand for our products, which may affect its financial condition and results of operations.

The company is exposed to foreign currency exchange rate fluctuations.

The company's inability to expand or effectively manage its growing distribution network may have an adverse effect on the company's business, results of operations and financial condition.

The company faces intense competition and may be unable to adapt to the rapid technological changes in the medical devices industry, which could adversely affect its business, results of operations and financial conditions.